Daraxonrasib pill doubles median survival in metastatic pancreatic cancer

An international phase‑III trial of the oral RAS‑targeting inhibitor daraxonrasib showed that patients with metastatic pancreatic ductal adenocarcinoma lived almost twice as long as those receiving standard chemotherapy. The study enrolled 500 participants across multiple research centers; 248 received daraxonrasib and 252 continued with physician‑chosen chemotherapy. Median overall survival was 13.2 months with the drug versus 6.7 months with chemotherapy, and progression‑free survival was 7.2 months versus 3.6 months, respectively. The death rate was also notably lower in the daraxonrasib group. The experimental therapy was developed by biotechnology firm Revolution Medicines and is still undergoing regulatory evaluation, meaning it is not yet approved for general clinical use.